Lupin slips after Q1 results

Lupin fell 3.95% to Rs 850.30 at 13:46 IST on BSE after consolidated net profit rose 43% to Rs 401.10 crore on 9.1% increase in net sales to Rs 2420.70 crore in Q1 June 2013 over Q1 June 2012.

The result was announced during trading hours today, 7 August 2013.

Meanwhile, the S&P BSE Sensex was down 104.11 points, or 0.56%, to 18,628.93.

On BSE, 99,000 shares were traded in the counter as against an average daily volume of 98,242 shares in the past one quarter.

The stock hit a high of Rs 895 and a low of Rs 847.60 so far during the day. The stock had hit a record high of Rs 908 on 19 July 2013. The stock had hit a 52-week low of Rs 540.15 on 11 October 2012.

The stock had outperformed the market over the past one month till 6 August 2013, rising 6.03% compared with the Sensex's 3.91% fall. The scrip had also outperformed the market in past one quarter, gaining 26.66% as against Sensex's 4.78% fall.

The large-cap company has an equity capital of Rs 89.56 crore. Face value per share is Rs 2.

Earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 43.5% to Rs 690.50 crore in Q1 June 2013 over Q1 June 2012.

Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations and active pharmaceutical ingredients.

Powered by Capital Market - Live News